Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

BSR_06_0059_A2_S99

— · F

6ff3287d-1749-56ed-a79a-604f4674b957

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
F
subtype
F

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MTORC1_SIGNALING+0.460
  • CHOLESTEROL_HOMEOSTASIS+0.450
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
  • HYPOXIA+0.440
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.440
  • ANGIOGENESIS+0.430
  • ANDROGEN_RESPONSE+0.410
  • GLYCOLYSIS+0.400
  • TGF_BETA_SIGNALING+0.400
  • TNFA_SIGNALING_VIA_NFKB+0.390

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.470
  • INTERFERON_GAMMA_RESPONSE-0.340
  • E2F_TARGETS-0.160
  • WNT_BETA_CATENIN_SIGNALING-0.130
  • ALLOGRAFT_REJECTION-0.120
  • MITOTIC_SPINDLE-0.120
  • APICAL_SURFACE-0.100
  • MYC_TARGETS_V2-0.050
  • ESTROGEN_RESPONSE_EARLY-0.040
  • G2M_CHECKPOINT-0.020

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_0209_T1_RNA
breast-umap@18
—C0.873
2TCGA-LL-A740-01A-21R-A32P-07
breast-umap@18
—F0.845
3TCGA-A2-A04W-01A-31R-A115-07
breast-umap@18
—C0.829
4SRR8518181
breast-umap@18
—F0.828
5SRR1313167
breast-umap@18
—C0.822
620040045.TNBC
breast-umap@18
—F0.817
7TCGA-18-3417-01A-01R-1443-07
lung-landscapes@6
—cohortSQ10.801
8TCGA-77-7338-01A-11R-2045-07
lung-landscapes@6
—cohortSQ20.788
9SRR1313160
breast-umap@18
—E0.787
10MBCProject_0006_T3_RNA
breast-umap@18
—A0.785

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 39 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MTORC1_SIGNALING0.460Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.450Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.450Inavolisib— uncovered
HYPOXIA0.440Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.440Inavolisib— uncovered
ANGIOGENESIS0.430Remibrutinib— uncovered
ANDROGEN_RESPONSE0.410Inavolisib— uncovered
GLYCOLYSIS0.400Inavolisib— uncovered
TGF_BETA_SIGNALING0.400Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.390Inavolisib— uncovered
HEDGEHOG_SIGNALING0.340Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.320Inavolisib— uncovered
NOTCH_SIGNALING0.300Inavolisib— uncovered
ADIPOGENESIS0.280Inavolisib— uncovered
COAGULATION0.270Binimetinib— uncovered
INFLAMMATORY_RESPONSE0.240Idelalisib— uncovered
IL2_STAT5_SIGNALING0.230Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.230Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.230Cobimetinib— uncovered
KRAS_SIGNALING_UP0.210Inavolisib— uncovered